Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The daily Top 10 COVID papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 56 articles:
HTML format



Single Articles


    February 2021
  1. LUO Q, Wu X, Zhang Y, Shu T, et al
    Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Cancer Lett. 2021;498:243.
    PubMed    


    January 2021
  2. BHARDWAJ V, Tan YQ, Wu MM, Ma L, et al
    Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Cancer Lett. 2021 Jan 8. pii: S0304-3835(21)00010.
    PubMed     Abstract available


    December 2020
  3. BUNGSY M, Palmer MCL, Jeusset LM, Neudorf NM, et al
    Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Cancer Lett. 2020 Dec 5. pii: S0304-3835(20)30649.
    PubMed     Abstract available


    November 2020
  4. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Cancer Lett. 2020 Nov 19. pii: S0304-3835(20)30603.
    PubMed     Abstract available


    August 2020
  5. TOCCI P, Cianfrocca R, Sestito R, Rosano L, et al
    Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30439.
    PubMed     Abstract available


    June 2020
  6. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available


    February 2020
  7. SHENG R, Li X, Wang Z, Wang X, et al
    Response to Comments on Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Feb 20. pii: S0304-3835(20)30068.
    PubMed    


  8. BERGSTEN TM, Burdette JE, Dean M
    Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.
    Cancer Lett. 2020 Feb 14. pii: S0304-3835(20)30080.
    PubMed     Abstract available


    January 2020
  9. YANG Y, Wei Q, Tang Y, Yuanyuan Wang, et al
    Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30043.
    PubMed     Abstract available


  10. WANG Y
    Comment on "Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer," Cancer Lett. 2020 Jan 2; 473 (2020) 139-147.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30045.
    PubMed    


  11. NAN X, Wang J, Cheng H, Yin Z, et al
    Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer Lett. 2020;469:195-206.
    PubMed     Abstract available


  12. SHENG R, Li X, Wang Z, Wang X, et al
    Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30665.
    PubMed     Abstract available


    December 2019
  13. LIU W, Wang W, Wang X, Xu C, et al
    Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
    Cancer Lett. 2019;472:59-69.
    PubMed     Abstract available


    November 2019
  14. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett 415 (20-29)].
    Cancer Lett. 2019 Nov 15. pii: S0304-3835(19)30561.
    PubMed    


    October 2019
  15. ALI R, Alabdullah M, Alblihy A, Miligy I, et al
    PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Cancer Lett. 2019 Oct 24. pii: S0304-3835(19)30538.
    PubMed     Abstract available


  16. GAO T, Zhang X, Zhao J, Zhou F, et al
    SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1alpha pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Cancer Lett. 2019 Oct 19. pii: S0304-3835(19)30526.
    PubMed     Abstract available


  17. ZHANG Z, Zhang L, Wang B, Wei R, et al
    MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
    Cancer Lett. 2019 Oct 17. pii: S0304-3835(19)30518.
    PubMed     Abstract available


  18. ASANTE DB, Calapre L, Ziman M, Meniawy TM, et al
    Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
    Cancer Lett. 2019 Oct 11. pii: S0304-3835(19)30511.
    PubMed     Abstract available


    July 2019
  19. CAUMANNS JJ, van Wijngaarden A, Kol A, Meersma GJ, et al
    Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer Lett. 2019 Jul 15. pii: S0304-3835(19)30400.
    PubMed     Abstract available


  20. PARAYATH NN, Gandham SK, Leslie F, Amiji MM, et al
    Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
    Cancer Lett. 2019;461:1-9.
    PubMed     Abstract available


    June 2019
  21. ZHANG M, Jabbari N, Satpathy M, Matyunina LV, et al
    Sequence diverse miRNAs converge to induce mesenchymal-to-epithelial transition in ovarian cancer cells through direct and indirect regulatory controls.
    Cancer Lett. 2019 Jun 1. pii: S0304-3835(19)30340.
    PubMed     Abstract available


    May 2019
  22. KREUZINGER C, von der Decken I, Wolf A, Gamperl M, et al
    Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Cancer Lett. 2019;459:1-12.
    PubMed     Abstract available


  23. FOGG KC, Olson WR, Miller JN, Khan A, et al
    Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.
    Cancer Lett. 2019 May 23. pii: S0304-3835(19)30324.
    PubMed     Abstract available


    March 2019
  24. HAN W, Zhang Y, Niu C, Guo J, et al
    BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
    Cancer Lett. 2019;445:45-56.
    PubMed     Abstract available


    November 2018
  25. RADHAKRISHNAN R, Ha JH, Jayaraman M, Liu J, et al
    Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30689.
    PubMed     Abstract available


    October 2018
  26. PENG Y, Kajiyama H, Yuan H, Nakamura K, et al
    PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Cancer Lett. 2018;442:181-192.
    PubMed     Abstract available


    August 2018
  27. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett. 2018 Feb 28; 415:20-29].
    Cancer Lett. 2018 Aug 18. pii: S0304-3835(18)30502.
    PubMed    


  28. KREITZBURG KM, Fehling SC, Landen CN, Gamblin TL, et al
    FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Cancer Lett. 2018 Aug 15. pii: S0304-3835(18)30527.
    PubMed     Abstract available


  29. CHEN X, Zhou J, Li X, Wang X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.
    Cancer Lett. 2018;435:80-91.
    PubMed     Abstract available


    July 2018
  30. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Abstract available


    June 2018
  31. MALDONADO L, Brait M, Izumchenko E, Begum S, et al
    Integrated Transcriptomic and Epigenomic Analysis of Ovarian Cancer Reveals Epigenetically Silenced GULP1.
    Cancer Lett. 2018 Jun 28. pii: S0304-3835(18)30436.
    PubMed     Abstract available


  32. ZHANG Q, Li Y, Miao C, Wang Y, et al
    Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.
    Cancer Lett. 2018 Jun 4. pii: S0304-3835(18)30390.
    PubMed     Abstract available


    April 2018
  33. MENG Y, Chen CW, Yung MMH, Sun W, et al
    DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30296.
    PubMed     Abstract available


  34. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Abstract available


    March 2018
  35. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Abstract available


  36. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Abstract available


    February 2018
  37. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Abstract available


  38. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Abstract available


    December 2017
  39. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Abstract available


    November 2017
  40. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Abstract available


    October 2017
  41. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Abstract available


  42. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Abstract available


  43. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Abstract available


    September 2017
  44. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Abstract available


    July 2017
  45. SAKAI K, Ukita M, Schmidt J, Wu L, et al
    Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
    Cancer Lett. 2017 Jul 19. pii: S0304-3835(17)30439.
    PubMed     Abstract available


    May 2017
  46. LAKSHMINARASIMHAN R, Andreu-Vieyra C, Lawrenson K, Duymich CE, et al
    Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
    Cancer Lett. 2017 May 5. pii: S0304-3835(17)30312.
    PubMed     Abstract available


    April 2017
  47. SOKOLENKO AP, Savonevich EL, Ivantsov AO, Raskin GA, et al
    Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Cancer Lett. 2017 Apr 1. pii: S0304-3835(17)30218.
    PubMed     Abstract available


    February 2017
  48. HU Y, Li D, Wu A, Qiu X, et al
    TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30109.
    PubMed     Abstract available


    January 2017
  49. DEAN M, Davis DA, Burdette JE
    Activin A Stimulates Migration of the Fallopian Tube Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical Signaling.
    Cancer Lett. 2017 Jan 20. pii: S0304-3835(17)30034.
    PubMed     Abstract available


    December 2016
  50. LUO T, Sun J, Zhu S, He J, et al
    Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30802.
    PubMed     Abstract available


  51. TODESCHINI P, Salviato E, Paracchini L, Ferracin M, et al
    Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts.
    Cancer Lett. 2016 Dec 22. pii: S0304-3835(16)30780.
    PubMed     Abstract available


  52. AUER K, Bachmayr-Heyda A, Aust S, Grunt TW, et al
    Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
    Cancer Lett. 2016 Dec 7. pii: S0304-3835(16)30739.
    PubMed     Abstract available


    November 2016
  53. JEONG JY, Kang HY, Kim TH, Kim GI, et al
    MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Cancer Lett. 2016 Nov 22. pii: S0304-3835(16)30705.
    PubMed     Abstract available


    September 2016
  54. YOU J, Liu J, Bao Y, Wang L, et al
    SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.
    Cancer Lett. 2016 Sep 30. pii: S0304-3835(16)30574.
    PubMed     Abstract available


  55. LI Q, Zhang C, Chen R, Xiong H, et al
    Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30561.
    PubMed     Abstract available


    March 2016
  56. TONG H, Ke JQ, Jiang FZ, Wang XJ, et al
    Tumor-associated macrophage-derived CXCL8 could induce ERalpha suppression via HOXB13 in endometrial cancer.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30196.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: